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Abstract:  
Background: Antibodies to prothrombin are detected by directly coating prothrombin on irradiated ELISA plates 
(aPT) or by using the phosphatidylserine/prothrombin complex as antigen (aPS/PT). Although these antibodies 
have both been associated with antiphospholipid syndrome (APS) and a correlation between the two assays have 
been reported, it seems that aPT and aPS/PTbelong to different populations of autoantibodies. Objectives: To 
systematically review the available evidence on aPT and aPS/PT antibodies and the risk of thrombosis in APS. 
Methods: Medline-reports published between 1988 and 2013 investigating aPT and aPS/PT as a risk factor for 
thrombosis were included. Whenever possible, antibody isotype(s) and site of thrombosis were analysed. Results: 
This systematic review is based on available data from more than 7000 patients and controls from 38 studies 
analyzing aPT and 10 aPS/PT. Antibodies to prothrombin (both aPT and aPS/PT) increased the risk thrombosis (OR 
2.3 [95%CI 1.72-3.5]). aPS/PT seemed to represent a stronger risk factor for thrombosis, both arterial and/or 
venous than aPT (OR 5.11 [95%CI 4.2-6.3] and 1.82 [95%CI 1.44-2.75], respectively). Conclusion: Routine 
measurement of aPS/PT (but not aPT) might be useful in establishing the thrombotic risk of patients with previous 
thrombosis and/or systemic lupus erythematosus. Their inclusion as laboratory criteria for the APS should be 
indisputably further explored. 
INTRODUCTION: Antiphospholipid antibodies (aPL) are a wide and heterogeneous family of immunoglobulin G, M 
and, less frequently A, initially thought to target negatively charged phospholipids (1). 2GPI) and the lupus2 
glycoprotein-I (anti-Although anticardiolipin (aCL), anti- anticoagulant (LA) are the routinely tested antibodies for 
the diagnosis of antiphospholipid syndrome (APS) (2), research on aPL is continuously expanding in the search for 
new clinically useful markers. Prothrombin, a plasma protein, was described as a cofactor for a ‘circulating 
anticoagulant’ by Loeliger in 1959 (3). Prothrombin is a common antigenic target for aPL, reported in around 50–
90% of patients with other aPL (4). Because antiprothrombin antibodies have heterogeneous immunologic and 
functional properties, their clinical significance is still under debate. Evidence of pathogenicity comes from animal 
model. Active immunization with prothrombin was associated with prothrombotic activity of blood in an ex-vivo 
mice model, producing direct evidence for thrombus induction by antibodies to prothrombin (5). Antibodies to 
prothrombin are usually detected by two different system assays, by directly coating prothrombin on irradiated 
ELISA plates (aPT) or by using the phosphatidylserine/prothrombin complex as antigen (aPS/PT). Although aPT 
and/or aPS/PT have both been associated with APS and a correlation between the two assays have been reported 
(6), it seems that aPT and aPS/PT belong to different populations of autoantibodies even though they can both be 
present in the same patient (7). 
Studies on the significance of antiprothrombin antibodies in thrombosis, including a systematic review (8) have 
shown controversial results. Therefore the value of antiprothrombin antibodies as markers of APS remains to be 
determined whilst the strength of the association of anti-prothrombin antibodies, detected either as aPT or 
aPS/PT, with thrombosis remains to be established. To contribute to this issue, we carried out a systematic review 
of the literature. In an attempt to summarise all available data on this subject, we selected papers whose design 
allowed us to objectively verify the clinical events and to establish the odds ratio with their 95% confidence 
interval (OR [95%CI]) for aPT and/or aPS/PT for thrombosis. Whenever possible, the antibody isotype(s) and the 
site of thrombosis were taken into account. 
Patients, materials, and methods  
Literature search and selection of studies  
Articles were identified by a computer-assisted search of the literature. The search strategy was applied to Ovid 
MEDLINE (R) In Process & other non-indexed citations and Ovid MEDLINE from 1988 through 2013. The grey 
literature was searched by applying a similar strategy to Google ScholarR , PubMedR and the Proquest 
Dissertation & Theses databases. Additional references were identified from manual review of the reference lists 
of included articles. A schematic representation of the search strategy, key words and subject terms used in the 
search is given in Figure 1. This approach has been previously reported and validated (8, 9). The search was 
further refined using the following limitations: “English language”and “human.” Review articles were excluded 
from the search. For aPT and aPS/PT we mainly focused on studies that met specific requirements such as 
specification of the temporal sequence between measurement of the antibodies and the events, or the presence 
of a control group besides the objective documentation of thrombosis. Prospective, crosssectional, case-control, 
and ambispective studies met these criteria, although retrospective studies were also included. All series of 7 or 
more patients were classified according to the aPL type and the underlying disease, and information about the 
study design and the assay methods was recorded. 
 Assessment of validity  
Study Selection 
Potential studies identified with the above search strategy were exported to an electronic reference management 
software program (RefWorks v.2.0). Duplicate studies were identified and removed using the filter functions 
“exact duplicates” and “close duplicates.” Two independent reviewers (SS, MLB) reviewed all potential studies. 
Eligibility was first determined by review of the title and abstract and then by full article review. Disagreements 
were resolved by consensus; if consensus could not be achieved, a third party (GS) would provide an assessment 
of eligibility. As the data on eligibility were dichotomous (eligible: yes / no), inter-rater agreement at both the title 
and abstract review and the full article review stages was determined by calculation of Cohen’s kappa coefficient 
(10). The patient population and laboratory methods were systematically esamine. 
Patient population: We noted whether eligibility criteria and confounding factors were specified for patients and, 
when included, controls. Patients were classified according to their underlying disease or syndrome. The major 
categories included systemic lupus erythematosus (SLE), other autoimmune diseases, non autoimmune diseases, 
arterial thrombosis, venous thrombosis and aPL positivity.  
Assay methods: Only studies that objectively verified the thromboembolic events were included. The following 
methods were considered: computerized ultrasonography or venography for deep vein thrombosis; radionuclide 
lung scanning or angiography for pulmonary embolism; arteriography for peripheral arterial occlusions; computed 
tomography, resonance imaging, or angiography for ischemic stroke; and electrocardiogram and cardiac enzymes 
for myocardial infarction. Among the details of thrombosis, we noted the site (arterial or venous) and whether it 
was the first episode or a recurrence. Only studies that objectively described the methodological approach for 
aPT and/or aPS/PT were included. We registered the aPT and aPS/PT antibody isotype (s) and how normal cut off 
was expressed (i.e. the number of standard deviations above the mean of controls, the multiple of the mean, the 
percentile, or quartile) (data not shown). In view of the current lack of standardization for these assays, the 
decision to include or exclude a study did not take into account the method used to detect aPL, as long as the 
determination of the cut-off values was fully detailed. Articles were then analyzed both pooled together and 
separately, according to the methods used for anti-prothrombin antibodies testing (i.e. aPT or aPS/PT). 
Statistical analysis 
 Odds ratios with 95% CI (OR [95%CI]) for arterial and/or venous thrombosis were recorded. If not available, they 
were calculated, whenever possible, by means of contingency tables. In case-control and cross-sectional studies, 
contingency tables were used to compare the proportion of aPT and/or aPS/PT in patients with and without 
thrombosis. In prospective studies, contingency tables were established as previously reported (8, 9). Briefly, if 
SLE was the enrolment criterion, the OR [95%CI] was calculated by comparing the proportion of aPT and/or 
aPS/PT antibodies in patients who did or did not develop thrombosis during followup. If thrombosis was the 
enrolment criterion, the OR [95%CI] was calculated by comparing the proportion of aPT and/or aPS/PT in patients 
with or without recurrent thrombosis during follow up. If positivity for aPL was the enrolment criterion, the OR 
[95%CI] was calculated by comparing the rates of thrombosis during follow-up of patients grouped according to 
different antibody types and titers. 
Risk of Bias Assessment  
One reviewer (SS) assessed the risk of bias of individual studies using the Newcastle-Ottawa Scale (NOS) for 
cohort studies, and the NOS for case control studies. The NOS is a scoring tool used to assess quality of evidence 
and risk of bias for non-randomized studies included in meta-analyses(11) The overall quality of evidence was 
determined using GRADE criterion and summarized using GRADE profiler (12). 
Results Literature search strategy and articles retrieved  
Sixty-six articles were retrieved: 48 investigated aPT (6, 7, 13-59) and 18 dealt with aPS/PT (6, 7, 24, 39, 43, 44, 52, 
57, 58, 60-68) (Figure 1). Of them, 7 studies (6, 7, 24, 39, 42, 43, 64) analyzed both aPT and aPS/PT. After full 
article review, 48 publications met the eligibility criteria for inclusion in the review (kappa 0.94). Two further 
publications (69, 70) were obtained from review of the reference lists of included articles; however they were 
excluded because it was not possible to differentiate APS patients with thrombosis from those with pregnancy 
morbidity. No further publications were obtained from review of the grey literature. The majority of the excluded 
articles for the following reasons: in 8 papers (49, 51, 61-65, 68), the OR [95%CI] for thrombosis was not provided 
and could not be calculated; 10 other studies (47, 48, 50, 53-59) were found not pertinent for the purpose of this 
review. The main characteristics of the remaining 48 articles are depicted in Tables 1 and 2. Overall, these studies 
provided information on 6006 patients and 1422 controls. Four prospective studies contributed with 417 patients. 
As most of the available studies were retrospective, we failed to separately analyze them on the basis of their 
design. In some studies healthy controls were involved only in the setting up of cut off values for aPT and/or 
aPS/PT testing. Indeed, they were reported but not 2GPI were theincluded in the analysis. SLE, APS, and the 
presence of LA, aCL and/or anti– enrolment criteria in 37 studies. Only 16 studies performed multivariate analysis 
using logistic regression, allowing a risk assessment analysing the joint contribution of each risk factor. 
Studies on aPT  
The OR with 95% CI of aPT for thrombosis were calculated in 38 studies on 5705 patients and 1262 controls (Table 
1, Figure 3). One study (42) used 2 methods to detect the antibodies and, therefore, results are reported for both 
of the assays. Overall, 22 (49%) of 45 associations reached significance: 2 of 7 associations with arterial 
thrombosis, 7 of 11 with venous thrombosis, and 13 of 27 with any thrombosis (as no distinction was possible 
between venous and arterial thrombosis). In one case, the association was confirmed after multivariate analysis 
only if associated to positive LA (26). Isotype analysis was performed in a few studies. These showed that IgG aPT 
were significantly associated with thrombosis as a whole in 6 out of 7 studies (86%) (6, 7, 31, 34, 38, 44, 46) and 
with venous thrombosis in 3 of 5 studies (60%) (6, 27, 43, 44, 71). No associations between IgG aPT with arterial 
thrombosis were reported (6, 42, 44, 71). IgM aPT was associated with thrombosis as a whole in 3 (42%) of 7 
studies (6, 7, 31, 34, 38, 44, 46). However, no associations were sustained after subgrouping between h arterial 
(6, 42, 44, 71) or venous thrombosis (6, 27, 43, 44, 71). Studies that included multivariate analysis are shown in 
Table 1. Overall, IgG aPT seemed more consistently associated with thrombosis than IgM antibodies. The lack of 
reference materials to quantify aPT meant we could not assess whether the risk correlated with their titers. 
Studies on aPS/PT 
 The OR [95%CI] of aPS/PT for thrombosis were available in 10 studies on 1775 patients and 628 controls (Table 2; 
Figure 4). Overall, 15 out of 18 analyses (83 %) reported significant associations: 3 out of 6 with arterial 
thrombosis, 4 out of 4 with venous thrombosis, and 8 out of 8 with thrombosis as a whole. Isotype analysis 
showed that IgG aPS/PT was associated with thrombosis as a whole, particularly with venous thrombosis in all the 
studies. Three studies failed to confirm the association between IgG aPS/PT and arterial thrombosis (39,55,62). 
The IgM isotype reached significance with thrombosis as a whole in all the studies but one (44). When analysed 
separately, the association with venous thrombosis was confirmed in all the studies, while the association with 
arterial events was confirmed in 2 studies (66, 67) out of 4 (Figure 4). Five studies (24, 52, 60, 66, 67) performed 
multivariate analysis. The association between aPS/PT and thrombosis as a whole and venous thrombosis was 
confirmed in all. In two studies, a significant association with arterial thrombosis was lost after multivariate 
analysis (37, 67). 
Comparison of aPT and aPS/PT  
There were 7 studies (6, 7, 24, 39, 42, 43, 64) that directly compared aPT and aPS/PT and their OR for thrombosis 
in 1196 Patients. When analysed within the same studies, aPS/PT is shown to be more strongly associated with 
thrombosis, both arterial and venous, than aPT. Overall, 10 out of 11 (90%) possible analyses derived from the 7 
studies reported a significant association between any thrombosis and aPS/PT compared to 5/11 for aPT. Analysis 
in relation to the type of thrombosis showed that aPS/PT only seemed to be associated with arterial events. The 
association with venous thrombosis was confirmed in all the studies for between aPS/PT and in 4 out 6 for aPT. 
DISCUSSION  
This systematic review of the literature aimed at establishing the strength of the association between anti-
prothrombin antibodies, tested either as aPT and/or aPS/PT, with thrombosis. Data on more than 7000 patients 
and controls from 38 studies analyzing aPT and 10 aPS/PT were available for our systematic review. Although 10 
studies measured aPS/PT, only 7 directly compared the odds ratio for thrombosis in about a thousand patients 
and controls. The aPS/PT antibodies were more significantly associated with thrombosis. Although indirect and 
potentially risky, comparison of the studies that analyzed only one antibody confirmed this increasing awareness. 
Overall, this review formally establishes aPS/PT are strong risk factors for thrombosis, irrespective of the site and 
type of thrombosis. aPS/PT have an odds ratio for thrombosis three to eighteen times higher than controls (6, 7, 
24, 39, 43, 44, 52, 57, 58, 60-68). As already demonstrated for Lupus Anticoagulant (28), the aPS/PT estimated risk 
is very close to that reported for deep vein thrombosis in patients with (72) and without (73) SLE. This risk has 
also been reported to be similar to and, in some instances, even higher than that in patients with genetically 
determined risk factors for venous thrombosis(74). 
Although the general population is unlikely to benefit from indiscriminate screening for these antibodies, their 
detection in patients with SLE, connective tissue diseases and/or previous thrombosis is justified by the high 
thrombotic risk associated with these clinical conditions. The aPT does not seem to be such a strong risk factor for 
APS, as less than 50% of their associations with thrombosis reached statistical significance. A sub-analysis of the 
different types of thrombosis showed that aPT are mainly associated with venous thrombosis although data 
available is vastly skewed. Whilst some data suggest that aPT antibodies are associated with thrombosis, a 
number of issues raise concern. Firstly, significant associations mainly come from retrospective studies, which 
contain a low level of evidence. Secondly, only a minority of studies confirm their findings by multivariate 
analysis. And finally, when the antibodies are analyzed in relation to the type of thrombosis, they are not 
associated with arterial events, and only marginally with thrombotic events as a whole. Overall, the potential role 
of aPT antibodies as laboratory tool for the diagnosis of APS still remains to be established. In this review we were 
unable to fully address the importance of antibody isotypes, as most studies investigated only IgG antibodies or 
did not distinguish between IgG and/or IgM. With these limitations, the association between IgM aPT and 
thrombosis is still elusive limiting their value in clinical practice. In contrast, our analysis strongly suggests that 
aPS/PT are associated with thrombosis. In this case, as well as per aPT, the fact that significant associations mainly 
came from retrospective studies, with a low level of evidence needs to be acknowledged. Intriguingly, despite a 
two-fold-increase in the risk for arterial thrombosis in aPS/PT positive, two recent studies failed in showing this 
association (60, 67). All in all, these findings need to be clearly substantiated by well-designed prospective clinical 
studies. The strengths of this analysis lie on a comprehensive search strategy, the inclusion of grey literature 
searches and manual review of reference lists minimized the risk of missing eligible studies. We performed 
independent and duplicate review for study selection, and data extraction. The use of the GRADE system and the 
NOS scale increases our confidence in our conclusions, and allows for reliable assessment of the quality of 
individual studies and the overall body of evidence. There are also limitations. All of the included studies were 
observational studies, subject to the biases inherent in this study design. The majority of the studies enrolled 
small numbers of patients, resulting in a loss of precision. Additionally, there was heterogeneity in the data. This 
resulted in the overall quality of the evidence being rated as “low,”as per GRADE criteria.Overall, based on our 
data, routine measurement of aPS/PT might be useful in establishing the thrombotic risk of patients with previous 
thrombosis and/or SLE. In conclusion, aPS/PT and not aPT seem to be a potential candidate as a laboratory tool 
for the diagnosis of APS whereas their inclusion as laboratory criteria for the APS should be indisputably explored. 
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Table 1: aPT and thrombosis: main characteristics of 38 articles on 5705 patients and 1262 controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SLE: systemic lupus erythematosus; APS: antiphospholipid syndrome; HC: healthy controls; aPL: antiphospholipid 
antibodies; DVT: deep vein thrombosis; 
IMA: ischemic myocardial attack; PAPS: Primary antiphospholipid syndrome; LA: lupus anticoagulant; VTE: venous 
thrombo- embolism; HCV: hepatitis C 
virus 
R: retrospective study; CS: cross-sectional study; CC: case-control study; L: longitudinal study; M: multivariate 
analysis 
Table 2: aPS/PT and thrombosis: main characteristics of 10 articles on 1775 patients and 628 controls 
 
 
 
 
 
 
 
 
 
SLE: systemic lupus erythematosus, APS: antiphospholipid syndrome, HC: healthy controls, PAPS: Primary 
antiphospholipid syndrome; R: retrospective study; M: multivariate analysis 
